Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression

Immunology

Volumn 92, Issue 3, 1997, Pages 402-406

  Trajkovic V ^a   Badovinac, V ^a   Popadic D ^b   Hadzic O ^b   Stojkovic M M ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTOXIFYLLINE;

ANIMAL CELL; ARTICLE; ASTROCYTE; AUTOIMMUNITY; CELL PROLIFERATION; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; EFFECTOR CELL; ENZYME INDUCTION; IMMUNOMODULATION; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

EID: 0030723024     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1997.00354.x     Document Type: Article

References (28)

1. NATHAN C. (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J 6, 3051.
2. LUKIĆ M.L., STOŠIĆ-GRUJIČIĆ S., OSTOJIĆ N., CHAN W.L. & LIEW F.Y. (1991) Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin in mice. Biochem Biophys Res Commun 178, 913.
3. FU Y. & BLANKENHORN E.P. (1992) Nitric oxide induced antimitogenic effects in high and low responder rat strains. J Immunol 148, 2217.
4. TAYLOR-ROBINSON A.W., LIEW F.Y., SEVERN A. et al. (1994) Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol 24, 980.
5. CHANG R.-H., LINFENG M.-H., LIU W.-H. & LAI M.-Z. (1997) Nitric oxide increased interleukin-4 expression in T lymphocytes. Immunology 90, 364.
6. BO L., DAWSON T.M., WESSELINGH S. et al. (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36, 778.
7. KOPROWSKI H., ZHENG Y.M., HEBER-KATZ E. et al. (1993) In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci USA 90, 3024.
8. CROSS A.H., MISKO T.P., LIN R.F. et al. (1994) Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 93, 2684.
9. RUULS S.R., VAN DER LINDEN S., SONTROP K., HUITINGA I. & DIJKSTRA C.D. (1996) Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. Clin Exp Immunol 103, 467.
10. STREITER R.M., REMICK D.G., WARD P.A. et al. (1988) Cellular and molecular regulation of tumor necrosis factor production by pentoxifylline. Biochem Biophys Res Comm 155, 1230.
11. NEUNER P., KLOSNER G., SCHAUER E. et al. (1994) Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells. Immunology 83, 262.
12. ROTT O., CASH E. & FLEISCHER B. (1993) Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type-1 but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 23, 1745.
13. RIENECK K., DIAMANT M., HAAHR P.M., SCHONHARTING M. & BENDTZEN K. (1993) In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 37, 131.
14. NEUNER P., KLOSNER G., POURMOJIB M., KNOBLER R. & SCWARZ T. (1997) Pentoxifylline in vivo and in vitro down-regulates the expression of intercellular adhesion molecule-1 in monocytes. Immunology 90, 435.
15. CONSTANTINESCU C.S., HILLIARD B., LAVI E. et al. (1996) Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline. J Neurol Sci 143, 14.
16. RIECKMAN P., WEBER F., GUNTHER A. & POSER S. (1996) The phosphodiesterase inhibitor pentoxifyline reduces early side effects of interferon-β1b treatment in patients with multiple sclerosis. Neurology 47, 64.
17. VADIEI K., TUCKER S.D., LOPEZBERESTEIN G. & WASAN K.M. (1996) Nephroprotective mechanism(s) of pentoxifylline-reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release. Pharmacol Toxicol 78, 174.
18. MCCARTHY K.D. & DE VELLIS J. (1980) Preparation of separate astroglia and oligodendrolial cell cultures from rat cerebral tissue. J Cell Biol 85, 890.
19. HIBBS J.B., TAINTOR R., VAVRIN Z. & RACHLIN E. (1989) Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157, 87.
20. CHOMCZYNSKI P. & SACCHI N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate phenol-chloroform extraction. Anal Biochem 162, 156.
21. HEWETT S.J., CORBETT J.A., MCDANIEL M.L. & CHOI D.W. (1993) Interferon-gamma and interleukin-1 beta induce nitric oxide formation from primary mouse astrocytes. Neurosci Lett 164, 229.
22. SIMMONS M.L. & MURPHY S. (1994) Roles for protein kinases in the induction of nitric oxide synthase in astrocytes. GLIA 11, 227.
23. SZABO C., SOUTHAN G.J. & THIEMERMAN C. (1994) Beneficial effects and improved survival in rodent models of septic shock with S-methylthiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 91, 12472.
24. RAMIREZ F. & SILVA A. (1997) Glucocorticoids enhance concanavalin A-induced mitogenic response through the inhibition of nitric oxide production. Immunology 90, 66.
25. MATSUMORI A., OKADA I., SHIOI T. et al. (1996) Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sci 10, 121.
26. GRETEN T.F., EIGLER A., SINHA B., MOELLER J. & ENDRES S. (1995) The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-α and nitric oxide. Int J Immunopharmacol 17, 605.
27. PAHAN K., NAMBOODIRI A.M.S., SHEIKH F.G., SMITH B.T. & SINGH I. (1997). Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J Biol Chem 272, 7786.
28. JEON Y.J., YANG K.H., PULASKI J.T. & KAMINSKI N.E. (1996) Attenuation of inducible nitric oxide synthase gene expression by delta (9)-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa-b/rel activation. Molec Pharmacol 50, 334.